Skip to main content
Clinical Trials/NCT03813290
NCT03813290
Recruiting
Not Applicable

A Neuro-Technological Intervention for Adolescents With Generalised Anxiety Disorder (GAD): A Feasibility Trial

National Healthcare Group, Singapore1 site in 1 country30 target enrollmentDecember 8, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Generalised Anxiety Disorder
Sponsor
National Healthcare Group, Singapore
Enrollment
30
Locations
1
Primary Endpoint
Usability Questionnaire
Status
Recruiting
Last Updated
11 months ago

Overview

Brief Summary

This study aims to evaluate the safety and acceptability of a basic neuro-technological intervention in the treatment of adolescents with Generalised Anxiety Disorder (GAD). Our technology will deliver a mindfulness-based anxiety regulation intervention through a neuro- / bio-feedback-based virtual reality (VR) game interface that is driven by a novel algorithm.

Detailed Description

This study is a single-arm open-label test of feasibility. The recruitment target is 30. Outpatient adolescents diagnosed with GAD will be recruited to undergo 8 x 30 minutes intervention sessions over 4 weeks. Participants who are enrolled will continue to receive treatment-as-usual prescribed by their treating psychiatrist, except for the use of psychotropics. This population is selected as they could elucidate whether our intervention can be beneficial as an early intervention program for GAD. During the 8 bi-weekly intervention sessions, participants will don a head-mounted VR display set and a mobile EEG-biosensor. The hardwares are non-invasive.

Registry
clinicaltrials.gov
Start Date
December 8, 2020
End Date
January 2026
Last Updated
11 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
National Healthcare Group, Singapore
Responsible Party
Principal Investigator
Principal Investigator

Lim Choon Guan

Senior Consultant and Deputy Chief

National Healthcare Group, Singapore

Eligibility Criteria

Inclusion Criteria

  • Between 13 to 18 years of age inclusive
  • Literate in English Language
  • Newly diagnosed with Generalised Anxiety Disorder: current episode, based on Computerised Diagnostic Interview Schedule for Children (C-DISC)
  • If on medication, dosage stable or unchanged for at least preceding 8 weeks
  • Has parental consent

Exclusion Criteria

  • Diagnosis (as defined by DSM-5) of: anxiety disorder induced by medication, substance, or another medical condition; obsessive compulsive disorder; bipolar disorder; any psychotic disorder (lifetime); intellectual disability (i.e. IQ\<70); autism spectrum disorder; attention-deficit/hyperactivity disorder
  • History of substance or drug use disorder (as per DSM-5 criteria) within the last 3 months
  • Neurological disorders or insults (e.g. epilepsy, cerebrovascular accidents)
  • Metal in the cranium, skull defects, or skin lesions on scalp (e.g. cuts, abrasion, rash) at proposed electrode sites
  • Irregular heart rhythms or heart problems
  • Severe visual or hearing impairment
  • Prior experience with mindfulness-based therapy (e.g. mindfulness-based stress reduction \[MBSR\], mindfulness-based cognitive therapy \[MBCT\])

Outcomes

Primary Outcomes

Usability Questionnaire

Time Frame: Week 4

Usability questionnaire measures participants' experience with the neuro-technological intervention devices and software. Subscale with12 items asking about overall comfort and usability are included, with scale range of 1 to 4 (1 - very false for me, 2 - False, 3 - True, 4 - Very true for me). Subsequent 27-items subscale measures participants' experience with the software/virtual reality experience, with scale ranging from 1 to 7 (the lower the rating, the poorer the experience). Total score will be obtained from summing up the scores for each subscale. Higher score means better overall experience with the intervention.

Secondary Outcomes

  • Multidimensional Anxiety Scale for Children (Parent-reported); 2nd Edition(Week 0, 5)
  • Multidimensional Anxiety Scale for Children (Adolescent-reported); 2nd Edition(Week 0, 5)

Study Sites (1)

Loading locations...

Similar Trials